

Agenda
Meeting of the Strategic Advisory Group of Experts on Immunization (SAGE)
14 – 16 April 2015
EB Room, WHO HQ, Geneva

Tuesday, 14 April 2015

Time	Session	Purpose of session, target outcomes and questions for SAGE	
9:00	Welcome – introduction of participants J. Abramson, Chair of SAGE		20 min.
9:20	Report from Director, IVB - Session 1 Global report including key updates and challenges from regions, J.-M. Okwo-Bele, WHO, 40 min. Discussion: 1h	FOR INFORMATION	1h 40 min.
10:00	Coffee/tea break	Break	30 min.
10:30	Report from Director, IVB - Session 1, (Contd.)		
11:30	Report from GAVI - Session 2 Report from the GAVI Alliance, S. Berkley, GAVI Alliance, 30 min. Discussion: 30 min.	FOR INFORMATION	1h
12:30	Lunch	Break	1h 40 min
14:10	Reports from other Advisory Committees on Immunization - Session 3 Report of the Global Advisory Committee on Vaccine Safety (GACVS), M. Wharton, Chair of GACVS, 10 min. Discussion: 10 min. Product Development for Vaccines Advisory Committee (PDVAC) criteria used for prioritizing vaccines for the work of the Initiative for Vaccine Research, D. Kaslow, Chair of PDVAC, 10 min. Discussion: 10 min.	FOR INFORMATION	40 min.

14:50	Coffee/tea break	Break	30 min.
15:20	<p>Global polio eradication initiative - Session 4</p> <p>Objective of the session; overview of Global Polio Eradication Initiative, H. Jafari, WHO, 15 min.</p> <p>Epidemiology of cVDPVs and updated SIA calendar, H. Jafari, WHO, 10 min.</p> <p>Report from SAGE WG (1. Contingency plan in case of prolonged cVDPV circulation and 2. WHO verification process of essential facilities), P. Figueroa, Chair of the Polio Working Group, 20 min.</p> <p>Discussion: 45 min.</p> <p>Updates on preparation for OPV2 withdrawal (e.g. IPV introduction, operationalizing OPV2 withdrawal, bOPV licensures and containment), M. Zaffran, WHO, 20 min.</p> <p>Discussion: 40 min.</p>	<p>FOR DISCUSSION AND DECISION</p> <p>For decision</p> <ul style="list-style-type: none"> • Review/endorse the contingency plans if persistent cVDPV2 continue to circulate • Review/endorse the proposed process for WHO to verify that essential poliovirus facilities certified by national authorities comply with GAP III <p>For information</p> <ul style="list-style-type: none"> • Review updated SIA calendar • Review updates on preparation for OPV2 withdrawal (e.g. Implementation support for tOPV-bOPV switch in OPV2 withdrawal) and bOPV licensure 	2h 30 min.
17:50	Cocktail		

Wednesday, 15 April 2015

08:30	Administration of multiple injectable vaccines - Session 5 Introduction, K. O'Brien , SAGE Member, 10 min. Summary of evidence on the administration of multiple injectable vaccines in infants: attitudes of healthcare providers and caregivers, A. Wallace, US CDC, 10 min. Acceptability of multiple injections during a single vaccination visit in South Africa and Tanzania, C. Wiysonge, University of Stellenbosch, 10 min. Summary of evidence on immune system effects, safety, administration practices and programmatic issues related to administration of multiple injectable vaccines during a single visit, S. Dolan, US CDC, 20 min. Summary of the findings and proposed recommendations, K. O'Brien, SAGE Member, 10 min. Discussion: 1h	FOR DISCUSSION SAGE recommendations on administration of multiple injectable vaccines to infants in a single visit.	2h
10:30	Coffee/tea break	Break	30 min.
11:00	Reducing pain and distress at the time of vaccination - Session 6 Introduction (importance, landscape analysis, objectives, and methods), N. Turner, SAGE member, 15 min. Impact of pain and distress at the time of vaccination, N. MacDonald, Dalhousie University, Halifax, 10 min. Systematic review of effectiveness and safety of interventions aimed at reducing pain and distress at the time of vaccination, A. Taddio, The Hospital for Sick Children, Toronto, 15 min. Proposed recommendations for reducing pain and distress at the time of vaccination, N. Turner, SAGE member, 20 min. Discussion: 1h	FOR DECISION Recommendations on potential interventions to reduce pain and distress at the time of vaccination	2h
13:00	Lunch	Break	1h

14:00	Sustainable Access to Vaccines in Middle Income Countries: a Shared Strategy - Session 7 Introduction of the session, Y. Al-Mazrou, SAGE Member, 5 min. The 'Middle Income Countries issue': reframing the problem. J. Andrus, Sabin Vaccine Institute, 15 min. A shared MICs strategy. T. Cernuschi, WHO and G. Gandhi, UNICEF, 20 min. Discussion: 80 min.	FOR INFORMATION AND DISCUSSION <ul style="list-style-type: none"> SAGE will be presented with the output of the MICs task force and the specific areas of the proposed comprehensive strategy and its related priority activities SAGE will be requested to indicate its concurrence with the general directions of the proposed MICs strategy and to provide any related suggestions for adjustment 	2h
16:00	Coffee/tea break		30 min.
16:30	Ebola vaccine and vaccination - Session 8 Introduction, O. Tomori, Co-chair of the SAGE working group on Ebola vaccines, 5 min. Update on the epidemiology of EVD, C. Dye, WHO, 10 min. Status of phase 1 and 2 trials and summary of preliminary results from phase 1 trials, V. Sathiyamoorthy, WHO, 15 min. Update on phase 3 trials (design and status), A.-M. Henao Restrepo, WHO, 10 min. (By telephone connection) Preparations for vaccine deployment, M.-P. Preziosi, WHO, 10 min. Framework for recommendations for deployment of vaccines, H. Rees, Co-chair of the SAGE working group on Ebola vaccines WG Co-chair, 10 min. Discussion: 1h	FOR INFORMATION AND DISCUSSION <ul style="list-style-type: none"> Provide SAGE with an update on the status of the current epidemic, vaccine clinical trials and an update on the process and scope of the recommendations that will be made by the WG and the preparatory work for deployment. Get input on the scope and framework of the WG for the issuance of recommendations on the deployment of vaccines 	2h
18:30	End of day		

Thursday, 16 April 2015

08:30	Maternal vaccination - Session 9 <p>Introduction, C.-A. Siegrist, SAGE member, 5 min.</p> <p>WHO's agenda on Maternal Immunization – an update, J. Hombach, WHO, 10 min.</p> <p>Review of influenza disease risk and incidence relevant to maternal immunization: Report from WHO IVIR-AC influenza working group, B. Gessner, Agence de Médecine Préventive, 15 min.</p> <p>Discussion: 10 min.</p> <p>Summary of the March maternal influenza meeting on new data and implementation, K. O'Brien, SAGE Member, 20 min.</p> <p>Discussion: 10 min.</p> <p>Implementation research gaps for furthering maternal immunization, J. Ortiz, WHO, 10 min.</p> <p>Discussion. 40 min.</p>	FOR INFORMATION AND DISCUSSION <ul style="list-style-type: none"> Update SAGE on the latest data , activities and achievements with respect to maternal immunization Solicit SAGE's input on the strategic directions for implementation research in support of maternal immunization 	2h
10:30	Coffee/tea break	Break	30 min.
11:00	Pertussis vaccination schedules - Session 10 <p>Introduction: Background and framing of the questions for SAGE, C.-A. Siegrist, Chair of the SAGE Pertussis Working Group, 10 min.</p> <p>Evidence in support/against various primary DTP vaccination schedules, E. Miller, Member of the SAGE Pertussis Working Group, 20 min.</p> <p>Modeling of impact of different DTP schedules. A. Clark, LSHTM, 15 min.</p> <p>Summary and recommendations, C.-A. Siegrist, Chair of the SAGE Pertussis Working Group, 15 min.</p> <p>Discussion: 1h 30 min.</p>	FOR DECISION <p>With primary focus on pertussis, review the evidence in support/against different schedules for DTP containing vaccines and the impact of different vaccination strategies.</p> <p>Update recommendations on the optimal schedules for DTP containing vaccines with a view to lead to the updating of the pertussis position paper.</p>	2h 30 min.
13:30	Closing		20 min.
13:50	End of meeting		